# An Effectiveness and Safety Study Comparing Oxybutynin Chloride Plus FLOMAX (Tamsulosin HCl) and Placebo Plus FLOMAX (Tamsulosin HCl) for the Treatment of Lower Urinary Tract Symptoms.

> **NCT00338624** · PHASE3 · COMPLETED · sponsor: **McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.** · enrollment: 420 (actual)

## Conditions studied

- Urination Disorders

## Interventions

- **DRUG:** oxybutynin chloride extended release

## Key facts

- **NCT ID:** NCT00338624
- **Lead sponsor:** McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** —
- **Final completion:** 2005-06
- **Target enrollment:** 420 (ACTUAL)
- **Last updated:** 2011-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00338624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00338624, "An Effectiveness and Safety Study Comparing Oxybutynin Chloride Plus FLOMAX (Tamsulosin HCl) and Placebo Plus FLOMAX (Tamsulosin HCl) for the Treatment of Lower Urinary Tract Symptoms.". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00338624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*